ClinicalTrials.gg

Program

TRK/RET Inhibitor ND-003

Also written as “ND-003 tablets”, “ND-003 Tablets” and “ND-003 40mg”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Shenzhen NewDEL Biotech.

Furthest: phase 2, since Oct 25, 20263 company-led studies, 3 open or runningNext primary completion: Jun 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen NewDEL Biotech33 open or runningphase 2since Oct 25, 2026Nov 23, 2023Jun 2028phase 1 · NCT06169579

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT06169579 · 96 planned · China
  2. Mar 28, 2024Phase 1 study in HealthyNCT06360874 · 104 planned · China
  3. Oct 25, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07929948 · 10 planned · China

Ahead

  1. Jun 2028Primary completion: phase 1 study in Advanced Solid TumorNCT06169579
  2. Jun 30, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07929948

TargetBeta

RET →read by rule
“An orally bioavailable small molecule inhibitor of multiple kinases, including tropomyosin-related-kinase (TRK) and rearranged during transfection (RET), ”NCIt, by rule

Other programs on RET

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
selpercatinibruleEli Lillyphase 419
pralsetinibruleHoffmann-La Rochephase 47
quizartinibruleDaiichi Sankyophase 322
RET Inhibitor HS-10365Hansoh Pharmaceutical Groupphase 23
RET Inhibitor FHND5071Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07929948Idiopathic Pulmonary Fibrosis · China2By invitationJun 30, 202810
NCT06360874Healthy · China1By invitationDec 2024104
NCT06169579Advanced Solid Tumor · China1By invitationJun 202896

How it is read

Names in the registry

  • “ND-003 tablets”, 8 entries
  • “ND-003 Tablets”, 1 entry
  • “ND-003 40mg”, 1 entry
  • “ND-003 80mg”, 1 entry
  • “ND-003 160mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.